Tamoxifen
Hormone Receptor-Positive Breast Cancer
Explore 112 assets in Hormone Receptor-Positive Breast Cancer →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fujian Cancer Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07581834CT.gov Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study | — | Recruiting | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05501704CT.gov ETHAN - ET for Male BC | — | Recruiting | — | — | — |
NCT04997941CT.gov Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT02668666CT.gov Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | — | Completed | — | — | — |
NCT02384239CT.gov A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02132000CT.gov Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone Receptor-Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamoxifen (this asset) | Fujian Cancer Hospital | P3 | BB · 67 |
| Exemestane | Fujian Cancer Hospital | P4 | BBB |
| Everolimus | Ellipses Pharma | P4 | BBB |
| Anastrozole | University of Illinois at Chicago | P4 | BBB |
| Palbociclib | BeOne Medicines | P3 | BBB |
| Ribociclib | BeOne Medicines | P4 | BBB |
| Abemaciclib | BeOne Medicines | P4 | BBB |
| Capecitabine | Kristina A. Fanucci | P4 | BBB |
| Carboplatin | Avenzo Therapeutics, Inc. | P3 | BB |
+42 more in the Hormone Receptor-Positive Breast Cancer cohort
Other indications for Tamoxifen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 75 |
| Invasive Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Fibroadenoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tamoxifen in Hormone Receptor-Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamoxifen-hormone-receptor-positive-breast-cancer-37984
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →